



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 168215

TO: Tamthom Truong  
Location: rem/5B19/5C18  
Art Unit: 1624  
Friday, October 14, 2005

Case Serial Number: 09/806836

From: Paul Schulwitz  
Location: Biotech-Chem Library  
REM-1A65  
Phone: 571-272-2527

Paul.schulwitz@uspto.gov

### Search Notes

Examiner Truong,

Please review the attached search results.

If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz  
Technical Information Specialist  
REM-1A65  
571-272-2527



L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:260277 HCAPLUS  
 DOCUMENT NUMBER: 132:293771  
 ENTRY DATE: Entered STN: 21 Apr 2000  
 TITLE: Preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors  
 INVENTOR(S): Hennequin, Laurent Francois Andre; Pasquet, Georges  
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 INT. PATENT CLASSIF.:  
 MAIN: C07D403-12  
 SECONDARY: C07D401-14; C07D405-14; C07D403-14; A61K031-517  
 CLASSIFICATION: 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

S.I.E.

Applicant's PCT


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021955	A1	20000420	WO 1999-GB3295	19991005 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344290	AA	20000420	CA 1999-2344290	19991005 <--
AU 9961128	A1	20000501	AU 1999-61128	19991005 <--
AU 756556	B2	20030116		
BR 9914326	A	20010626	BR 1999-14326	19991005 <--
EP 1119567	A1	20010801	EP 1999-947758	19991005 <--
EP 1119567	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527436	T2	20020827	JP 2000-575861	19991005 <--
NZ 510434	A	20031031	NZ 1999-510434	19991005 <--
AT 294796	E	20050515	AT 1999-947758	19991005 <--
ZA 2001002655	A	20020930	ZA 2001-2655	20010330
NO 2001001739	A	20010607	NO 2001-1739	20010406 <--
PRIORITY APPLN. INFO.:			EP 1998-402496	A 19981008
			WO 1999-GB3295	W 19991005 <--

## PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000021955	ICM	C07D403-12
	ICS	C07D401-14; C07D405-14; C07D403-14; A61K031-517
WO 2000021955	ECLA	C07D401/14+239+231+213; C07D401/14+239+231+211; C07D403/12+239+231; C07D403/14+249+239+231; C07D405/14+307B+239+231; C07D521/00B1E2A
		MARPAT 132:293771

OTHER SOURCE(S):

GRAPHIC IMAGE:



**ABSTRACT:**

The title compds. [I; ring C = 5-6 membered heterocyclic moiety; Z = O, NH, S, CH<sub>2</sub>; R<sub>1</sub> = H, alkyl, alkoxymethyl, etc.; n = 0-5; m = 0-3; R<sub>2</sub> = H, OH, halo, etc.] and their salts which inhibit the effects of VEGF, and therefore useful in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepared and formulated. E.g., a multi-step synthesis of quinazoline II was given. Compds. I are effective at 1-50 mg/kg/day.

SUPPL. TERM:           quinazoline prepn VEGF receptor tyrosine kinase inhibitor;  
                          angiogenesis inhibitor quinazoline prepn; vascular  
                          permeability quinazoline prepn

INDEX TERM:           Blood vessel  
                          (permeability, reducing; preparation of quinazolines as VEGF  
                          receptor tyrosine kinase inhibitors)

INDEX TERM:           Angiogenesis inhibitors  
                          (preparation of quinazolines as VEGF receptor tyrosine kinase  
                          inhibitors)

INDEX TERM:           Vascular endothelial growth factor receptors  
                          ROLE: BSU (Biological study, unclassified); MSC  
                          (Miscellaneous); BIOL (Biological study)  
                          (preparation of quinazolines as VEGF receptor tyrosine kinase  
                          inhibitors)

INDEX TERM:           264207-46-7P 264207-48-9P  
                          264207-50-3P 264207-52-5P  
                          264207-54-7P 264207-56-9P  
                          264207-58-1P 264207-60-5P  
                          264207-62-7P 264207-64-9P  
                          264207-66-1P 264207-68-3P  
                          264207-70-7P 264207-72-9P  
                          264207-74-1P 264207-76-3P  
                          264207-78-5P 264207-80-9P  
                          264207-82-1P 264207-84-3P  
                          264207-86-5P 264207-88-7P  
                          264207-90-1P 264207-92-3P  
                          264207-94-5P 264207-96-7P  
                          264207-98-9P 264208-00-6P  
                          264208-02-8P 264208-04-0P  
                          264208-06-2P 264208-08-4P  
                          264208-10-8P 264208-12-0P  
                          264208-14-2P 264208-16-4P  
                          264208-18-6P 264208-21-1P  
                          264208-23-3P 264208-26-6P  
                          264208-28-8P 264208-31-3P

264208-33-5P 264208-35-7P  
264208-38-0P 264208-41-5P  
264208-43-7P

ROLE: BAC (Biological activity or effector, except adverse);  
BSU (Biological study, unclassified); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(preparation of quinazolines as VEGF receptor tyrosine kinase  
inhibitors)

## INDEX TERM:

104-97-2, 3-Cyclopentylpropionyl chloride 109-01-3,  
1-Methylpiperazine 109-70-6, 1-Bromo-3-chloropropane  
109-86-4, 2-Methoxyethanol 111-77-3, 2-(2-  
Methoxyethoxy)ethanol 121-34-6, 4-Hydroxy-3-methoxybenzoic  
acid 446-32-2, 2-Amino-4-fluorobenzoic acid 617-05-0,  
Ethyl 4-hydroxy-3-methoxybenzoate 838-57-3, Ethyl  
4-nitrobenzoylacetate 1126-09-6, Ethyl  
4-piperidinecarboxylate 1479-24-9, Ethyl  
2-fluorobenzoylacetate 1572-10-7 1615-14-1,  
1H-Imidazole-1-ethanol 2033-24-1, 2,2-Dimethyl-1,3-dioxane-  
4,6-dione 2058-49-3 2881-63-2, Ethyl  
4-chlorobenzoylacetate 2881-83-6, Ethyl  
4-methoxybenzoylacetate 3249-68-1 4687-37-0, Ethyl  
3,4-dimethoxybenzoylacetate 4860-93-9 5653-40-7,  
4,5-Dimethoxyanthranilic acid 6283-81-4 6482-24-2,  
2-Bromoethyl methyl ether 7357-67-7, 3-Morpholinopropyl  
chloride 18997-19-8, Chloromethyl pivalate 19541-95-8  
24979-46-2 26377-17-3, Ethyl isonicotinoylacetate  
35087-28-6 35087-29-7 36878-91-8, Ethyl 3-furoylacetate  
52119-38-7, Ethyl 3-nitrobenzoylacetate 55120-06-4  
60547-98-0, 2-Amino-4-benzyloxy-5-methoxybenzamide  
63131-29-3, Methyl 4-fluorobenzoylacetate 74731-63-8,  
2-(1,2,3-Triazol-1-yl)ethanol 78583-81-0 78597-54-3  
208519-10-2 209224-91-9 264209-14-5 264209-16-7  
264209-19-0 264209-20-3 264209-22-5

ROLE: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of quinazolines as VEGF receptor tyrosine kinase  
inhibitors)

## INDEX TERM:

1578-89-8P 4891-32-1P 13790-39-1P,  
4-Chloro-6,7-dimethoxyquinazoline 13794-72-4P  
16499-57-3P 29211-70-9P 50931-94-7P  
54945-13-0P 59719-19-6P 69678-02-0P 101421-76-5P  
123855-51-6P 142851-03-4P 166815-96-9P  
179688-01-8P 193002-24-3P  
193002-25-4P 193002-30-1P  
193002-31-2P 193002-32-3P 196194-41-9P  
196194-42-0P 196194-43-1P 196194-44-2P  
196194-45-3P 196194-62-4P  
196194-86-2P 196194-88-4P  
196195-13-8P 196603-84-6P 196603-85-7P  
196603-86-8P 196603-87-9P 199327-54-3P 1993  
28-74-0P 199328-77-3P 199328-78-4P  
220896-22-0P 220896-27-5P  
220896-29-7P 264208-45-9P 264208-47-1P  
264208-49-3P 264208-51-7P  
264208-53-9P 264208-55-1P 264208-58-4P  
264208-60-8P 264208-63-1P 264208-66-4P  
264208-69-7P 264208-72-2P 264208-79-9P  
264208-83-5P 264208-86-8P 264208-89-1P  
264208-92-6P 264208-95-9P

264208-98-2P 264209-01-0P 264209-04-3P  
264209-07-6P 264209-09-8P  
264209-11-2P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP  
(Preparation); RACT (Reactant or reagent)  
(preparation of quinazolines as VEGF receptor tyrosine kinase  
inhibitors)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD.


REFERENCE(S): (1) Glaxo; WO 9935132 A 1999 HCAPLUS  
(2) Rhone-Poulenc; WO 9515758 A 1995 HCAPLUS  
(3) Rhone-Poulenc; WO 9639145 A 1996 HCAPLUS

IT 264207-46-7P 264207-48-9P 264207-50-3P  
264207-52-5P 264207-54-7P 264207-56-9P  
264207-58-1P 264207-60-5P 264207-62-7P  
264207-64-9P 264207-66-1P 264207-68-3P  
264207-70-7P 264207-72-9P 264207-74-1P  
264207-76-3P 264207-78-5P 264207-80-9P  
264207-82-1P 264207-84-3P 264207-86-5P  
264207-88-7P 264207-90-1P 264207-92-3P  
264207-94-5P 264207-96-7P 264207-98-9P  
264208-00-6P 264208-02-8P 264208-04-0P  
264208-06-2P 264208-08-4P 264208-10-8P  
264208-12-0P 264208-14-2P 264208-16-4P  
264208-18-6P 264208-21-1P 264208-23-3P  
264208-26-6P 264208-28-8P 264208-31-3P  
264208-33-5P 264208-35-7P 264208-38-0P  
264208-41-5P 264208-43-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors)


RN 264207-46-7 HCAPLUS

CN Quinazoline, 6,7-dimethoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA  
INDEX NAME)




RN 264207-48-9 HCAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(phenylmethyl)-  
1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264207-50-3 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 264207-52-5 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 264207-54-7 HCAPLUS

CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 264207-56-9 HCAPLUS


CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 264207-58-1 HCAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 264207-60-5 HCAPLUS  
 CN Quinazoline, 7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (5:3) (9CI) (CA INDEX NAME)



●3/5 HCl


RN 264207-62-7 HCAPLUS  
 CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (2:5) (9CI) (CA INDEX NAME)






● 5/2 HCl

RN 264207-64-9 HCAPLUS  
CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (20:17) (9CI) (CA INDEX NAME)




● 17/20 HCl

RN 264207-66-1 HCAPLUS  
CN Quinazoline, 4-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264207-68-3 HCAPLUS

CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264207-70-7 HCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264207-72-9 HCAPLUS

CN Quinazoline, 4-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264207-74-1 HCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264207-76-3 HCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 264207-78-5 HCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-80-9 HCAPLUS

CN 4-Quinazolinamine, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-82-1 HCAPLUS

CN 4-Quinazolinamine, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-84-3 HCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methylphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-86-5 HCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-88-7 HCAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-90-1 HCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)-, hydrochloride (5:12) (9CI) (CA INDEX NAME)




●12/5 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-92-3 HCAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-, hydrochloride (5:9) (9CI) (CA INDEX NAME)




●9/5 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-94-5 HCAPLUS


CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]-, hydrochloride (9CI) (CA INDEX NAME)






●x HCl


RN 264207-96-7 HCAPLUS  
 CN Quinazoline, 4-[[5-(2-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264207-98-9 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-nitrophenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-00-6 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-02-8 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-propyl-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-04-0 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pentenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-06-2 HCAPLUS  
 CN Quinazoline, 6-methoxy-4-[[5-(methoxymethyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-08-4 HCAPLUS  
 CN Quinazoline, 4-[[5-ethyl-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-10-8 HCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(2-phenylethyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-12-0 HCAPLUS  
 CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 264208-14-2 HCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 264208-16-4 HCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidiny]methoxy]- (9CI) (CA INDEX NAME)




RN 264208-18-6 HCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-21-1 HCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-23-3 HCAPLUS

CN Quinazoline, 4-[(5-butyl-1H-pyrazol-3-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-26-6 HCAPLUS

CN Quinazoline, 4-[[5-(2-cyclopentylethyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-28-8 HCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-31-3 HCAPLUS

CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 264208-33-5 HCAPLUS

CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 264208-35-7 HCAPLUS

CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy] - (9CI) (CA INDEX NAME)




RN 264208-38-0 HCAPLUS

CN Quinazoline, 7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy] - (9CI)




(CA INDEX NAME)




RN 264208-41-5 HCAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-43-7 HCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 13790-39-1P, 4-Chloro-6,7-dimethoxyquinazoline 13794-72-4P

16499-57-3P 179688-01-8P 193002-24-3P

193002-25-4P 193002-30-1P 193002-31-2P

193002-32-3P 196194-44-2P 196194-45-3P

196194-62-4P 196194-86-2P 196194-88-4P

196195-13-8P 199327-54-3P 199328-74-0P

199328-77-3P 199328-78-4P 220896-22-0P

220896-27-5P 220896-29-7P 264208-49-3P

264208-51-7P 264208-53-9P 264208-55-1P

264208-69-7P 264208-72-2P 264208-86-8P

264208-89-1P 264208-92-6P 264208-95-9P

264208-98-2P 264209-07-6P 264209-09-8P


264209-11-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors)


RN 13790-39-1 HCAPLUS

CN Quinazoline, 4-chloro-6,7-dimethoxy- (8CI, 9CI) (CA INDEX NAME)




RN 13794-72-4 HCAPLUS

CN 4(1H)-Quinazolinone, 6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 16499-57-3 HCAPLUS

CN 4(1H)-Quinazolinone, 7-fluoro- (9CI) (CA INDEX NAME)




RN 179688-01-8 HCAPLUS

CN 4(1H)-Quinazolinone, 6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 193002-24-3 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-4-oxo-7-(phenylmethoxy)-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 193002-25-4 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, (7-hydroxy-6-methoxy-4-oxo-3(4H)-quinazolinyl)methyl ester (9CI) (CA INDEX NAME)




RN 193002-30-1 HCAPLUS

CN Quinazoline, 4-chloro-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 193002-31-2 HCAPLUS


CN Propanoic acid, 2,2-dimethyl-, [7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 193002-32-3 HCAPLUS  
CN 4(1H)-Quinazolinone, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 196194-44-2 HCAPLUS  
CN 4(1H)-Quinazolinone, 6-methoxy-7-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 196194-45-3 HCAPLUS  
CN Quinazoline, 4-chloro-6-methoxy-7-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 196194-62-4 HCAPLUS  
CN 4(1H)-Quinazolinone, 6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 196194-86-2 HCAPLUS  
CN 4(1H)-Quinazolinone, 7-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 196194-88-4 HCAPLUS  
CN Quinazoline, 4-chloro-7-(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 196195-13-8 HCAPLUS  
CN Quinazoline, 4-chloro-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 199327-54-3 HCAPLUS  
CN Quinazoline, 4-chloro-7-(2-methoxyethoxy) - (9CI) (CA INDEX NAME)




RN 199328-74-0 HCAPLUS  
CN Quinazoline, 4-chloro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy] - (9CI) (CA INDEX NAME)




RN 199328-77-3 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 199328-78-4 HCAPLUS

CN 4(1H)-Quinazolinone, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 220896-22-0 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-4-oxo-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 220896-27-5 HCAPLUS


CN Quinazoline, 6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 220896-29-7 HCAPLUS  
 CN Quinazoline, 4-chloro-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy] - (9CI)  
 (CA INDEX NAME)




RN 264208-49-3 HCAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, [7-(3-chloropropoxy)-6-methoxy-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 264208-51-7 HCAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 264208-53-9 HCAPLUS  
 CN 4(1H)-Quinazolinone, 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 264208-55-1 HCAPLUS  
 CN Quinazoline, 4-chloro-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 264208-69-7 HCAPLUS  
CN 4(1H)-Quinazolinone, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI)  
(CA INDEX NAME)



RN 264208-72-2 HCAPLUS  
CN Quinazoline, 4-chloro-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI)  
(CA INDEX NAME)




RN 264208-86-8 HCAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[3-[(2,2-dimethyl-1-oxopropoxy)methyl]-3,4-dihydro-6-methoxy-4-oxo-7-quinazolinyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 264208-89-1 HCAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-4-oxo-7-(4-piperidinylmethoxy)-3(4H)-quinazolinyl]methyl ester, hydrochloride (9CI) (CA INDEX NAME)






●x HCl


RN 264208-92-6 HCAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)




RN 264208-95-9 HCAPLUS  
CN 4(1H)-Quinazolinone, 6-methoxy-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)




RN 264208-98-2 HCAPLUS  
CN Quinazoline, 4-chloro-6-methoxy-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 264209-07-6 HCAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-oxo-3(4H)-quinazolinyl]methyl ester (9CI) (CA INDEX NAME)



RN 264209-09-8 HCAPLUS  
 CN 4(1H)-Quinazolinone, 6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA  
 INDEX NAME)



RN 264209-11-2 HCAPLUS  
 CN Quinazoline, 4-chloro-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA  
 INDEX NAME)

